BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26274939)

  • 21. CSF3R is mutated in chronic neutrophilic leukemia and atypical CML.
    Cancer Discov; 2013 Jul; 3(7):OF23. PubMed ID: 23847367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.
    Rocca S; Carrà G; Poggio P; Morotti A; Brancaccio M
    Mol Cancer; 2018 Feb; 17(1):40. PubMed ID: 29455651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomics of chronic neutrophilic leukemia.
    Maxson JE; Tyner JW
    Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice.
    Tefferi A; Elliott M; Pardanani A
    Curr Opin Hematol; 2015 Mar; 22(2):171-6. PubMed ID: 25575036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
    Dao KH; Solti MB; Maxson JE; Winton EF; Press RD; Druker BJ; Tyner JW
    Leuk Res Rep; 2014; 3(2):67-9. PubMed ID: 25180155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
    Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
    Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL.
    Tran A; Wong M
    Blood; 2021 Dec; 138(26):2890. PubMed ID: 34967865
    [No Abstract]   [Full Text] [Related]  

  • 28. How I treat atypical chronic myeloid leukemia.
    Gotlib J
    Blood; 2017 Feb; 129(7):838-845. PubMed ID: 27899359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, in a 5-Month Baby - ARare Presentation.
    Saqlain N; Ahmed N
    J Coll Physicians Surg Pak; 2016 Nov; 26(11):103-105. PubMed ID: 28666496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature.
    Wang L; Du F; Zhang HM; Wang HX
    Braz J Med Biol Res; 2015 Jul; 48(7):583-7. PubMed ID: 26017341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical chronic myeloid leukaemia with trisomy 13: a case report.
    Guo-yu H; Chao-hui Y; Kui T; Zhen-zhen C
    Chin Med Sci J; 2011 Dec; 26(4):254-6. PubMed ID: 22218057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
    Elsayed M; Harry S; Nanua S; Zaidi S; Habib MH; Raza S
    Cureus; 2022 Jul; 14(7):e26619. PubMed ID: 35949766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
    Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
    BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New mutations in myeloproliferative neoplasms; 2014 update].
    Kirito K
    Rinsho Ketsueki; 2014 Oct; 55(10):1833-40. PubMed ID: 25297747
    [No Abstract]   [Full Text] [Related]  

  • 35. Atypical chronic myeloid leukemia: a rare entity with management challenges.
    Dhakal P; Gundabolu K; Amador C; Rayamajhi S; Bhatt VR
    Future Oncol; 2018 Jan; 14(2):177-185. PubMed ID: 29226717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
    Carreño-Tarragona G; Álvarez-Larrán A; Harrison C; Martínez-Ávila JC; Hernández-Boluda JC; Ferrer-Marín F; Radia DH; Mora E; Francis S; González-Martínez T; Goddard K; Pérez-Encinas M; Narayanan S; Raya JM; Singh V; Gutiérrez X; Toth P; Amat-Martínez P; Mcilwaine L; Alobaidi M; Mayani K; McGregor A; Stuckey R; Psaila B; Segura A; Alvares C; Davidson K; Osorio S; Cutting R; Sweeney CP; Rufián L; Moreno L; Cuenca I; Smith J; Morales ML; Gil-Manso R; Koutsavlis I; Wang L; Mead AJ; Rozman M; Martínez-López J; Ayala R; Cross NCP
    Blood Adv; 2023 May; 7(9):1672-1681. PubMed ID: 36375042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
    Fend F; Horn T; Koch I; Vela T; Orazi A
    Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia-aCML).
    Martino G; Quintini M; Martelli MP; Ascani S; Lazzi S; Mecucci C
    Am J Hematol; 2023 Jul; 98(7):1163-1164. PubMed ID: 36594191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.
    Itonaga H; Ota S; Ikeda T; Taji H; Amano I; Hasegawa Y; Ichinohe T; Fukuda T; Atsuta Y; Tanizawa A; Kondo T; Miyazaki Y
    Leuk Res; 2018 Dec; 75():50-57. PubMed ID: 30458320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
    Talati C; Padron E
    Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.